Medical experts in Australia and New Zealand are cautiously exploring the role of psychedelic therapy in palliative care.
Surveys indicate that 75% of palliative care doctors disagree with the notion that psychedelics are unsafe for clinical settings.
Research emphasizes the importance of combining these therapies with psychological support to address existential distress in patients.
Legislation in Australia and New Zealand is beginning to allow for the authorized medical prescription of psilocybin and MDMA.